Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2011-04-12
2011-04-12
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S724000
Reexamination Certificate
active
07923471
ABSTRACT:
The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis.
REFERENCES:
patent: 4131651 (1978-12-01), Shah et al.
patent: 4370325 (1983-01-01), Packman
patent: 4409205 (1983-10-01), Shively
patent: 4744980 (1988-05-01), Holly
patent: 4818537 (1989-04-01), Guo
patent: 4883658 (1989-11-01), Holly
patent: 4914088 (1990-04-01), Glonek et al.
patent: 4966773 (1990-10-01), Gressel et al.
patent: 5041434 (1991-08-01), Lubkin
patent: 5075104 (1991-12-01), Gressel et al.
patent: 5174988 (1992-12-01), Mautone et al.
patent: 5278151 (1994-01-01), Korb et al.
patent: 5290572 (1994-03-01), MacKeen
patent: 5294607 (1994-03-01), Glonek et al.
patent: 5371108 (1994-12-01), Korb et al.
patent: 5441951 (1995-08-01), Serhan
patent: 5578586 (1996-11-01), Glonek et al.
patent: 5696166 (1997-12-01), Yanni et al.
patent: 5800807 (1998-09-01), Hu et al.
patent: 5958912 (1999-09-01), Sullivan
patent: 6153607 (2000-11-01), Pflugfelder et al.
patent: 6645978 (2003-11-01), Gamache et al.
patent: WO 00/03705 (2000-01-01), None
patent: WO 01/05388 (2001-01-01), None
patent: WO 01/34144 (2001-05-01), None
Lee et al., “Inhibition of Leukotriene B4-induced Neutrophil Migration by Lipoxin A4: Structure-Function Relationships,”Biiochemical and Biophysical Research Communications, vol. 180(3), pp. 1416-1421 (1991).
Lemp et al., “Report of the Natioal Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes,”CLAO, vol. 21(4), pp. 221-231 (1995).
Marsh et al., “Topical Nonpreserved Methylprednisolone Therapy for Keratoconjunctivitis Sicca in Sjogren Syndrome,”Ophthalmology, vol. 106(1), pp. 811-816 (1999).
McCulley et al., “Tear Film Structure and Dry Eye,”Contactologia, vol. 20, pp. 145-149 (1998).
Shine et al., “Keratoconjunctivitis Sicca Associated with Meibomian Secretion Polar Lipid Abnormality,”Archives of Ophthalmology, vol. 116, pp. 849-852 (1998).
Tauber et al.,Lacrimal Gland, Tear Film and Dry Eye Syndromes 2edited by Sullivan et al., Plenum Press, New York (1998), “A Dose Rangining Clinical Trial to Assess the Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients with Keratoconjunctivitis Sicca,” pp. 969-972.
Nan Chiang, et al., “The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo,” Pharmacological Reviews, 2006, pp. 463-487, vol. 58, No. 3.
Fiore, et al., “Induction of Functional Lipoxin A4 Receptors in HL-60 Cells,” Blood, Jun. 15, 1993, pp. 3395-3403, vol. 81, No. 12.
Karsten Gronert, et al., “Selectivity of Recombinant Human Leukotriene D4, Leukotriene B4, and Lipoxin A4 Receptors with Aspirin-Triggered 15-epi-LXA4 and Regulation of Vascular and Inflammatory Responses,” American Journal of Pathology, Jan. 2001, pp. 3-9, vol. 158, No. 1.
Karsten Gronert, et al., “A Role for the Mouse 12/15-Lipoxygenase Pathway in Promoting Epithelial Wound Healing and Host Defense,” The Journal of Biological Chemistry, Apr. 15, 2005, pp. 15267-15278, vol. 280, No. 15.
Gamache Daniel A.
Hellberg Mark R.
Klimko Peter G.
Alcon Inc.
Krass Frederick
Packard Benjamin
Ryan Patrick M.
LandOfFree
Method of treating dry eye disorders and uveitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating dry eye disorders and uveitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating dry eye disorders and uveitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2691693